Rel-benzyl (((3s,5s)-1-oxaspiro[2.3]hexan-5-yl)methyl)carbamate

Catalog No. :
ACFELR381
CAS No. :
2814153-85-8
Molecular Formula :
C14H17NO3
Molecular Weight :
247.29

IUPAC Name:benzyl (((3s,5s)-1-oxaspiro[2.3]hexan-5-yl)methyl)carbamate

Rel-benzyl (((3s,5s)-1-oxaspiro[2.3]hexan-5-yl)methyl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$322.00Login to see priceInquiryInquiry
250mg95%$483.00Login to see priceInquiryInquiry
500mg95%$805.00Login to see priceInquiryInquiry
1g95%$1288.00Login to see priceInquiryInquiry
5g95%$3862.00Login to see priceInquiryInquiry
10g95%$6436.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameRel-benzyl (((3s,5s)-1-oxaspiro[2.3]hexan-5-yl)methyl)carbamate
IUPAC Namebenzyl (((3s,5s)-1-oxaspiro[2.3]hexan-5-yl)methyl)carbamate
Molecular FormulaC14H17NO3
Molecular Weight247.29
SMILESO=C(OCC1=CC=CC=C1)NC[C@@H](C2)C[C@]32CO3
InChI KeyNZLGCABZTLCNKP-XBXGTLAGSA-N
Synonym5-[Cbz-amino(methyl)]-1-oxaspiro[2.3]hexane | F78117 | F78118 | Benzyl ((1-oxaspiro[2.3]hexan-5-yl)methyl)carbamate | BENZYL N-(1-OXASPIRO[2.3]HEXAN-5-YLMETHYL)CARBAMATE | Rel-benzyl (((3r,5r)-1-oxaspiro[2.3]hexan-5-yl)methyl)carbamate | Rel-benzyl (((3s,
CAS No.2814153-85-8
PubChem CID155892616

Synthetic Route by SureRoute

1. ACFELR381 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACNXUH296 route compound structure diagram
    ACNXUH2961774-47-6 In Stock
  2. Plus
  3. ACVMHN027 route compound structure diagram
    ACVMHN0271869903-79-6 In Stock
  4. Then
  5. ACFELR381 route product structure diagram
    ACFELR3812814153-85-8
Inquiry

2. ACFELR381 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFELR381 route product structure diagram
    ACFELR3812814153-85-8
Inquiry

Comments (0)